Enanta Pharmaceuticals, Inc. · NASDAQ:ENTA

Enanta Pharmaceuticals — ICAR 2023: 36th International Conference on Antiviral Research

12 slides from Enanta Pharmaceuticals's conference presentation, Mar 15, 2023

  1. Slide 1: EDP-235, an Oral 3CL Protease Inhibitor for COVID-19, Suppresses Viral Replication and Transmission in Ferrets

    EDP-235, an Oral 3CL Protease Inhibitor for the Treatment of COVID-19, Suppresses Viral Replication and Transmission in SARS-CoV-2- Infected Ferrets Michael H. J. Rhodin, Anand Balakrishnan, Archie Reyes, Michael Vaine, Tessa Cressey, Miranda Crepeau, Nicole McAllister, Ruichao Shen, Kellye Daniels,

  2. Slide 2: Disclosures

    Disclosures: Michael H. J. Rhodin, Anand Balakrishnan, Archie Reyes, Michael Vaine, Tessa Cressey, Miranda Crepeau, Nicole McAllister, Ruichao Shen, Kellye Daniels, Daniel Leonard, Indy Zang, Lijuan Jiang, Guoqiang Wang, Yat Sun Or, and Bryan Goodwin are/were employees of Enanta Pharmaceuticals. Ric

  3. Slide 3: EDP-235: A Novel, Oral Protease Inhibitor Designed for COVID-19

    EDP-235: A Novel, Oral Protease Inhibitor Designed for COVID-19 • Potent and selective inhibition of SARS-CoV-2 3CLpro enzyme • Potent inhibition of SARS-CoV-2 replication in multiple cellular SARS-CoV-2 models • Activity retained against SARS-CoV-2 variants, including Omicron variants • Other human

  4. Slide 4: EDP-235: Highly Potent 3CLpro Inhibitor that Retains Activity Against SARS-CoV-2 Variants

    EDP-235: Highly Potent 3CLpro Inhibitor that Retains Activity Against SARS-CoV-2 Variants Assay Variant / Lineage (mutation) Potency [nM] Omicron (P132H) 4.1 ± 0.8 [B.1.1.529, BA.2, BA.5, BA.2.75, BQ.1, BQ1.1, XBB.1] Alpha [Original] / Delta* [B.1.617.2] 5.8 ± 3.7 B.1.1.318 (T21I) 2.0 ± 0.1 Biochemi

  5. Slide 5: Animal Models of COVID-19

    Animal Models of COVID-19 • Animal models of COVID-19 are indispensable for the discovery and characterization of novel antiviral agents targeting SARS-CoV-2 • Variation in the structure of the SARS-CoV-2 host receptor (ACE2) limits the animal species that can be used to study this virus – SARS-CoV-

  6. Slide 6: EDP-235 Ferret Pharmacokinetics

    EDP-235 Ferret Pharmacokinetics Ferret drug exposure levels well-aligned with human Ph1 PK data • Single dose ferret PK study with 200 mg/kg and 500 mg/kg EDP-235, Ferret C24 Cmax Tmax t1/2 AUC0-24 PO Dose Sex N (ng/mL) (ng/mL) (hr) (hr) (hr•µg/mL) Plasma [ng/mL] Mean: 2597 9410 4.3 6.7 92.2 200 mg/

  7. Slide 7: Ferret Model: Study Design

    Ferret Model: Study Design Primary Readouts: - Nasal lavages: live virus + qPCR - Nasal turbinate tissues: end of study live virus + qPCR 1 - Transmission to uninfected animals 2 3 1• 3 Cohorts: Vehicle Control (placebo), 200 mg/kg EDP-235 QD, and 200 mg/kg EDP-235 BID 2• Therapeutic dosing study (1

  8. Slide 8: EDP-235 is Efficacious in a Ferret Model of COVID: Robust Antiviral Treatment Effect & Prevention of Transmission

    EDP-235 is Efficacious in a Ferret Model of COVID: Robust Antiviral Treatment Effect & Prevention of Transmission Primary Readouts: - Nasal lavages: live virus + qPCR - Nasal turbinate tissues: end of study live virus + qPCR - Transmission to uninfected animals Infect Daily Nasal Lavage: Live Virus

  9. Slide 9: EDP-235 is Efficacious in a Ferret Model of COVID: Robust Antiviral Treatment Effect & Prevention of Transmission

    EDP-235 is Efficacious in a Ferret Model of COVID: Robust Antiviral Treatment Effect & Prevention of Transmission Primary Readouts: - Nasal lavages: live virus + qPCR - Nasal turbinate tissues: end of study live virus + qPCR - Transmission to uninfected animals Infect Co-house Sac d.0 Sac Infected C

  10. Slide 10: Summary

    Summary Antiviral Treatment Effect: • EDP-235 treatment of SARS-CoV-2 infected animals resulted in a rapid and robust decline in viral replication and viral RNA levels Transmission Prevention: • Infected, untreated animals went on to infect healthy co-housed contact animals • Infected, EDP-235-treat

  11. Slide 11: EDP-235 Profile Suggests Potential for Best-in-Class Antiviral Treatment for SARS-CoV-2 Infection

    EDP-235 Profile Suggests Potential for Best-in-Class Antiviral Treatment for SARS-CoV-2 Infection • Potent antiviral activity in vitro against SARS-CoV-2 variants, including Omicron variants • Generally safe and well-tolerated in adult healthy volunteers up to 400 mg for up to 7 days • Targeting an

  12. Slide 12: www.enanta.com

    Ei: Enanta Pharmaceuticals www.enanta.com

Enanta Pharmaceuticals — ICAR 2023: 36th International Conference on Antiviral Research on 6ix